Rebecca Miksad | Profiles RNS

Rebecca Miksad, MD

Associate Professor

Boston University Chobanian & Avedisian School of Medicine

Medicine

Hematology & Medical Oncology

MD, Cornell University
MMS/MMSc, Harvard University
MPH, Harvard School of Public Health
BA, Harvard University

Websites

	Boston Medical Center Provider Profile
	Flatiron Health
	LinkedIn
	Google Scholar
	Twitter
	ResearchGate

ORCID : 0000-0003-3194-5122

Rebecca Miksad is a medical oncologist and health outcomes researcher who serves as senior medical director at Flatiron Health. In this role, Rebecca focuses on generating real-world evidence, establishing regulatory-grade quality standards and contributing to the development of clinically-relevant methods to real-world data evaluation and analyses.

Rebecca maintains a clinical practice at Boston Medical Center. A nationally recognized clinician and researcher, Rebecca regularly publishes in leading medical journals, serves on national committees and lectures internationally.

Prior to joining Flatiron Health, Rebecca was an assistant professor at Harvard Medical School, senior scientist at the Institute for Technology Assessment at Massachusetts General Hospital, and director of gastrointestinal oncology and gastrointestinal oncology clinical trials at Beth Israel Deaconess Medical Center (BIDMC). Rebecca’s academic research focused on improving cancer treatment decision-making through better characterization of patient outcomes and increasing relevance of clinical trial endpoints. Rebecca earned a BA cum laude in economics from Harvard University and an MD with honors in research from Cornell University. She was a resident in internal medicine at Cornell University/New York-Presbyterian Hospital, and completed hematology and medical oncology fellowships at Harvard Medical School/BIDMC. Rebecca earned a MMS from Harvard Medical School and an MPH in Clinical Effectiveness from the Harvard School of Public Health in clinical effectiveness (with an emphasis on decision science). She also completed a post-doctoral fellowship in the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training (PCORT).

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Miksad RA, Sarkar S. Evaluating Cancer Screening in the Era of Advanced Causal Inference Methods: Innovation, Adherence, and Health Equity Considerations. JCO Clin Cancer Inform. 2025 Jan; 9:e2400214. PMID: 39792989

Miksad RA. Real-World Evidence in Regulatory Decision Making: Time for Evidence Integration. Clin Pharmacol Ther. 2024 Nov; 116(5):1153-1155. PMID: 39404680

Canavan ME, Wang X, Ascha MS, Miksad RA, Showalter TN, Calip GS, Gross CP, Adelson KB. Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors. JAMA Oncol. 2024 Jul 01; 10(7):887-895. PMID: 38753341; PMCID: PMC11099840; DOI: 10.1001/jamaoncol.2024.1129;

Miksad RA, Calip GS. Future of Cancer Treatment Guidelines: Integrating Real-World Insights for Equitable Cancer Care. JCO Clin Cancer Inform. 2024 Jun; 8:e2400081. PMID: 38959447

Miksad RA, Ryals CA. The US Food and Drug Administration Dual Mandate for Rapid Drug Review and Equity. JAMA Netw Open. 2024 May 01; 7(5):e2411447. PMID: 38691364

Vidal GA, Jain N, Fisher A, Sheinson D, Lofgren KT, Ma E, Yu E, Comment L, Miksad R, Sincan M, Martin RL, Zuniga R, Daniel D. Racial and Ethnic Inequities at the Practice and Physician Levels in Timely Next-Generation Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer Treated in the US Community Setting. JCO Oncol Pract. 2024 Mar; 20(3):370-377. PMID: 38194619

Guadamuz JS, Wang X, Ryals CA, Miksad RA, Snider J, Walters J, Calip GS. Socioeconomic status and inequities in treatment initiation and survival among patients with cancer, 2011-2022. JNCI Cancer Spectr. 2023 Aug 31; 7(5). PMID: 37707536; PMCID: PMC10582690; DOI: 10.1093/jncics/pkad058;

Canavan M, Wang X, Ascha M, Miksad R, Showalter TN, Calip G, Gross CP, Adelson K. End-of-Life Systemic Oncologic Treatment in the Immunotherapy Era: The Role of Race, Insurance, and Practice Setting. J Clin Oncol. 2023 Oct 20; 41(30):4729-4738. PMID: 37339389; PMCID: PMC10602547; DOI: 10.1200/JCO.22.02180;

Goyal G, Lau KW, Wang X, Davidoff AJ, Huntington SF, Jamy O, Calip G, Shah H, Stephens DM, Miksad R, Parikh RB, Takvorian S, Neparidze N, Seymour EK. The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Netw Open. 2023 Jun 01; 6(6):e2316642. PMID: 37273206; PMCID: PMC10242428; DOI: 10.1001/jamanetworkopen.2023.16642;

Abou-Alfa GK, Wang X, Parrinello CM, Gossai A, Kim R, Magee K, Miksad RA. Association between posttreatment a-fetoprotein reduction and outcomes in real-world US patients with advanced hepatocellular carcinoma. Cancer. 2023 Jul 01; 129(13):2064-2074. PMID: 36942492

Showing 10 of 97 results. Show More

Liu Q, Mathur R, Xu Y, Torres AZ, Miksad RA, Liu C, Smithson H, Wang Y, Zhu H, Booth B, Huang SM, Zhi J, Sridhara R, Blumenthal GM, Larkins E, Mishra-Kalyani PS, Rivera DR, Kluetz PG, Sharon E. The Association Between Baseline Hepatic or Renal Function and Clinical Outcomes for Patients With Non-Small Cell Lung Cancer Treated With a PD-1/PD-L1 Blocking Antibody Using Real-World and Trial Data. Clin Pharmacol Ther. 2023 May; 113(5):1139-1149. PMID: 36790088

Canavan ME, Wang X, Ascha MS, Miksad RA, Calip GS, Gross CP, Adelson KB. Systemic Anticancer Therapy at the End of Life-Changes in Usage Pattern in the Immunotherapy Era. JAMA Oncol. 2022 Dec 01; 8(12):1847-1849. PMID: 36264566; PMCID: PMC9585458; DOI: 10.1001/jamaoncol.2022.4666;

Jaber Chehayeb R, Hood A, Wang X, Miksad R, Schellhorn Mougalian S, Lustberg MB, Wang SY, Greenup RA, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. JAMA Netw Open. 2022 Nov 01; 5(11):e2244204. PMID: 36445704; PMCID: PMC9709649; DOI: 10.1001/jamanetworkopen.2022.44204;

Calip GS, Cohen A, Rohrer R, Wang X, Wang X, Webster A, Wu A, Griffith SD, Showalter TN, Miksad RA. Telemedicine use among patients with metastatic breast cancer during the COVID-19 pandemic: Differences by race, age, and region. Pharmacoepidemiol Drug Saf. 2023 Jan; 32(1):66-72. PMID: 36111444; PMCID: PMC10091805; DOI: 10.1002/pds.5541;

Coombs L, Orlando A, Wang X, Shaw P, Rich AS, Lakhtakia S, Titchener K, Adamson B, Miksad RA, Mooney K. A machine learning framework supporting prospective clinical decisions applied to risk prediction in oncology. NPJ Digit Med. 2022 Aug 16; 5(1):117. PMID: 35974092; PMCID: PMC9380664; DOI: 10.1038/s41746-022-00660-3;

Torres AZ, Nussbaum NC, Parrinello CM, Bourla AB, Bowser BE, Wagner S, Tabano DC, George D, Miksad RA. Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types. Adv Ther. 2022 Jun; 39(6):2831-2849. PMID: 35430670; PMCID: PMC9123022; DOI: 10.1007/s12325-022-02091-8;

Parikh RB, Takvorian SU, Vader D, Paul Wileyto E, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Neparidze N, Miksad RA, Calip GS, Hearn CM, Ferrell W, Shulman LN, Mamtani R, Hubbard RA. Impact of the COVID-19 Pandemic on Treatment Patterns for Patients With Metastatic Solid Cancer in the United States. J Natl Cancer Inst. 2022 Apr 11; 114(4):571-578. PMID: 34893865; PMCID: PMC9002283; DOI: 10.1093/jnci/djab225;

Calip GS, Wadé NB, Guadamuz JS, Wang X, Miksad RA, Whitaker KD. Disparities in cardiovascular disease mortality after breast cancer treatment: Methodological considerations using real-world data. Cancer. 2022 02 15; 128(4):647-650. PMID: 34873685

Kelley RK, Miksad R, Cicin I, Chen Y, Klümpen HJ, Kim S, Lin ZZ, Youkstetter J, Hazra S, Sen S, Cheng AL, El-Khoueiry AB, Meyer T, Abou-Alfa GK. Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade. Br J Cancer. 2022 03; 126(4):569-575. PMID: 34621044; PMCID: PMC8854685; DOI: 10.1038/s41416-021-01532-5;

Parikh RB, Takvorian SU, Vader D, Wileyto EP, Clark AS, Lee DJ, Goyal G, Rocque GB, Dotan E, Geynisman DM, Phull P, Spiess PE, Kim RY, Davidoff AJ, Gross CP, Neparidze N, Miksad RA, Calip GS, Hearn CM, Ferrell W, Shulman LN, Mamtani R, Hubbard RA. Impact of the COVID-19 pandemic on treatment patterns for US patients with metastatic solid cancer. medRxiv. 2021 Sep 23. PMID: 34611665; PMCID: PMC8491856; DOI: 10.1101/2021.09.22.21263964;

Stein SM, Snider J, Ali SM, Miksad RA, Alexander BM, Castellanos E, Schrock AB, Madison R, Swaminathan A, Venstrom JM, McCusker M. Real-world association of HER2/ERBB2 concordance with trastuzumab clinical benefit in advanced esophagogastric cancer. Future Oncol. 2021 Nov; 17(31):4101-4114. PMID: 34463133

Tan K, Bryan J, Segal B, Bellomo L, Nussbaum N, Tucker M, Torres AZ, Bennette C, Capra W, Curtis M, Miksad RA. Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data. Clin Pharmacol Ther. 2022 01; 111(1):168-178. PMID: 34197637; PMCID: PMC9292216; DOI: 10.1002/cpt.2351;

Bockorny B, Bullock AJ, Abrams TA, Faintuch S, Alsop DC, Goldberg SN, Ahmed M, Miksad RA. Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma. Dig Dis Sci. 2022 Jul; 67(7):3455-3463. PMID: 34297268

Miksad RA, Calip GS. Early-onset pancreatic cancer research: Making sense of confounding and bias. Cancer. 2021 10 01; 127(19):3505-3507. PMID: 34228811

Calip GS, Miksad RA, Sarkar S. Time-Related Biases in Nonrandomized COVID-19-Era Studies Using Real-world Data. JAMA Oncol. 2021 Jun 17. PMID: 34137793

Asemota J, Oladunjoye O, Babalola A, Nwosu U, Liu PS, Oladunjoye AO, Castro-Webb N, Miksad RA. Comparison of Hepatocellular Carcinoma in Hispanic and Non-Hispanic Patients. Cureus. 2021 May 07; 13(5):e14884. PMID: 34104609; PMCID: PMC8180179; DOI: 10.7759/cureus.14884;

Goyal L, Sirard C, Schrag M, Kagey MH, Eads JR, Stein S, El-Khoueiry AB, Manji GA, Abrams TA, Khorana AA, Miksad R, Mahalingam D, Zhu AX, Duda DG. Phase I and Biomarker Study of the Wnt Pathway Modulator DKN-01 in Combination with Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer. Clin Cancer Res. 2020 12 01; 26(23):6158-6167. PMID: 32878766

Leapman MS, Presley CJ, Zhu W, Soulos PR, Adelson KB, Miksad RA, Boffa DJ, Gross CP. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Netw Open. 2020 06 01; 3(6):e207205. PMID: 32511721; PMCID: PMC7280954; DOI: 10.1001/jamanetworkopen.2020.7205;

Stinchcombe TE, Miksad RA, Gossai A, Griffith SD, Torres AZ. Real-World Outcomes for Advanced Non-Small Cell Lung Cancer Patients Treated With a PD-L1 Inhibitor Beyond Progression. Clin Lung Cancer. 2020 09; 21(5):389-394.e3. PMID: 32409266

Aggarwal H, Sheffield KM, Li L, Lenis D, Sorg R, Barzi A, Miksad R. Primary tumor location and survival in colorectal cancer: A retrospective cohort study. World J Gastrointest Oncol. 2020 Apr 15; 12(4):405-423. PMID: 32368319; PMCID: PMC7191328; DOI: 10.4251/wjgo.v12.i4.405;

Griffith SD, Tucker M, Bowser B, Calkins G, Chang CJ, Guardino E, Khozin S, Kraut J, You P, Schrag D, Miksad RA. Author's Response to "A Letter in Support of Real-World RECIST". Adv Ther. 2020 04; 37(4):1691-1693. PMID: 32056085; PMCID: PMC7140733; DOI: 10.1007/s12325-020-01246-9;

Barzi A, Miksad R, Surinach A, Corvino FA, Wang S, Torres AZ, Mamlouk K, Pulgar S, Valderrama A, Bekaii-Saab T, Ahn D. Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States. Pancreas. 2020 02; 49(2):193-200. PMID: 32011529; PMCID: PMC7028474; DOI: 10.1097/MPA.0000000000001479;

Balogh EP, Bindman AB, Eckhardt SG, Halabi S, Harvey RD, Jaiyesimi I, Miksad R, Moses HL, Nass SJ, Schilsky RL, Sun S, Torrente JM, Warren KE. Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs. Oncologist. 2020 03; 25(3):e405-e411. PMID: 32162805; PMCID: PMC7066705; DOI: 10.1634/theoncologist.2019-0698;

Miksad R, Cicin I, Chen Y, Klumpen H, Kim S, Lin Z, Youkstetter J, Sen S, Cheng A, Meyer T, Kelley R, Abou-Alfa G. Outcomes based on Albumin-Bilirubin (ALBI) grade in the phase 3 CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC). Ann Oncol. 2019 Jul; 30 Suppl 4:iv134. PMID: 32085040

Miksad RA, Ogasawara S, Xia F, Fellous M, Piscaglia F. Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: the LiverT study. BMC Cancer. 2019 Aug 13; 19(1):795. PMID: 31409405; PMCID: PMC6693268; DOI: 10.1186/s12885-019-5989-2;

Khozin S, Miksad RA, Adami J, Boyd M, Brown NR, Gossai A, Kaganman I, Kuk D, Rockland JM, Pazdur R, Torres AZ, Zhi J, Abernethy AP. Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer. Cancer. 2019 Nov 15; 125(22):4019-4032. PMID: 31381142; PMCID: PMC6899461; DOI: 10.1002/cncr.32383;

Griffith SD, Miksad RA, Calkins G, You P, Lipitz NG, Bourla AB, Williams E, George DJ, Schrag D, Khozin S, Capra WB, Taylor MD, Abernethy AP. Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set. JCO Clin Cancer Inform. 2019 08; 3:1-13. PMID: 31403818; PMCID: PMC6873982; DOI: 10.1200/CCI.19.00013;

Stewart M, Norden AD, Dreyer N, Henk HJ, Abernethy AP, Chrischilles E, Kushi L, Mansfield AS, Khozin S, Sharon E, Arunajadai S, Carnahan R, Christian JB, Miksad RA, Sakoda LC, Torres AZ, Valice E, Allen J. An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non-Small-Cell Lung Cancer. JCO Clin Cancer Inform. 2019 07; 3:1-15. PMID: 31335166; PMCID: PMC6873914; DOI: 10.1200/CCI.18.00155;

O'Neill T, Miksad R, Miller D, Maloney L, John A, Hiller C, Hornberger J. ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products. Value Health. 2019 07; 22(7):754-761. PMID: 31277820

Griffith SD, Tucker M, Bowser B, Calkins G, Chang CJ, Guardino E, Khozin S, Kraut J, You P, Schrag D, Miksad RA. Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer. Adv Ther. 2019 08; 36(8):2122-2136. PMID: 31140124; PMCID: PMC6822856; DOI: 10.1007/s12325-019-00970-1;

Miksad RA, Samant MK, Sarkar S, Abernethy AP. Small But Mighty: The Use of Real-World Evidence to Inform Precision Medicine. Clin Pharmacol Ther. 2019 07; 106(1):87-90. PMID: 31112289; PMCID: PMC6617709; DOI: 10.1002/cpt.1466;

Ng K, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, Schrag D, Miksad R, Bullock AJ, Allen J, Zuckerman D, Chan E, Chan JA, Wolpin BM, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Ganser C, Wilkinson B, Mackintosh C, Zheng H, Hollis BW, Meyerhardt JA, Fuchs CS. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. JAMA. 2019 04 09; 321(14):1370-1379. PMID: 30964527; PMCID: PMC6459117; DOI: 10.1001/jama.2019.2402;

Khozin S, Carson KR, Zhi J, Tucker M, Lee SE, Light DE, Curtis MD, Bralic M, Kaganman I, Gossai A, Hofmeister P, Torres AZ, Miksad RA, Blumenthal GM, Pazdur R, Abernethy AP. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval. Oncologist. 2019 05; 24(5):648-656. PMID: 30591549; PMCID: PMC6516117; DOI: 10.1634/theoncologist.2018-0307;

Abou-Alfa GK, Miksad RA, Tejani MA, Williamson S, Gutierrez ME, Olowokure OO, Sharma MR, El Dika I, Sherman ML, Pandya SS. A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma. Oncologist. 2019 02; 24(2):161-e70. PMID: 30352941; PMCID: PMC6369956; DOI: 10.1634/theoncologist.2018-0654;

Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2019 01 01; 25(1):80-89. PMID: 30190369; PMCID: PMC6320284; DOI: 10.1158/1078-0432.CCR-18-0847;

Liu PH, Huo TI, Miksad RA. Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies. Semin Liver Dis. 2018 08; 38(3):242-251. PMID: 30041276

Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, Gouw A, Kagen A, Klimstra D, Komuta M, Kondo F, Miksad R, Nakano M, Nakanuma Y, Ng I, Paradis V, Nyun Park Y, Quaglia A, Roncalli M, Roskams T, Sakamoto M, Saxena R, Sempoux C, Sirlin C, Stueck A, Thung S, Tsui WMS, Wang XW, Wee A, Yano H, Yeh M, Zen Y, Zucman-Rossi J, Theise N. cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology. 2018 07; 68(1):113-126. PMID: 29360137; PMCID: PMC6340292; DOI: 10.1002/hep.29789;

Qian ZR, Rubinson DA, Nowak JA, Morales-Oyarvide V, Dunne RF, Kozak MM, Welch MW, Brais LK, Da Silva A, Li T, Li W, Masuda A, Yang J, Shi Y, Gu M, Masugi Y, Bui J, Zellers CL, Yuan C, Babic A, Khalaf N, Aguirre A, Ng K, Miksad RA, Bullock AJ, Chang DT, Tseng JF, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar M, Wollison B, Laing A, Hahn WC, Meyerson M, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Wolpin BM. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2018 Mar 08; 4(3):e173420.View Related Profiles.

Tseng, Jennifer
Miksad, Rebecca

PMID: 29098284; PMCID: PMC5844844; DOI: 10.1001/jamaoncol.2017.3420;

Miksad RA, Meropol NJ. Carcinoembryonic Antigen-Still More to Learn From the Real World. JAMA Oncol. 2018 03 01; 4(3):315-316. PMID: 29270625

Miksad RA, Abernethy AP. Harnessing the Power of Real-World Evidence (RWE): A Checklist to Ensure Regulatory-Grade Data Quality. Clin Pharmacol Ther. 2018 02; 103(2):202-205. PMID: 29214638; PMCID: PMC5814721; DOI: 10.1002/cpt.946;

Bullock A, Stuart K, Jacobus S, Abrams T, Wadlow R, Goldstein M, Miksad R. Capecitabine and oxaliplatin as first and second line treatment for locally advanced and metastatic pancreatic ductal adenocarcinoma. J Gastrointest Oncol. 2017 Dec; 8(6):945-952. PMID: 29299353; PMCID: PMC5750180; DOI: 10.21037/jgo.2017.06.06;

Jahn B, Rochau U, Kurzthaler C, Hubalek M, Miksad R, Sroczynski G, Paulden M, Bundo M, Stenehjem D, Brixner D, Krahn M, Siebert U. Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online. BMC Cancer. 2017 Oct 16; 17(1):685. PMID: 29037213; PMCID: PMC5644100; DOI: 10.1186/s12885-017-3603-z;

Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Bui JL, Yuan C, Qian ZR, Babic A, Da Silva A, Nowak JA, Khalaf N, Brais LK, Welch MW, Zellers CL, Ng K, Chang DT, Miksad RA, Bullock AJ, Tseng JF, Swanson RS, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Hornick JL, Ogino S, Fuchs CS, Hezel AF, Koong AC, Wolpin BM. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Br J Cancer. 2017 Dec 05; 117(12):1874-1882.View Related Profiles.

Tseng, Jennifer
Miksad, Rebecca

PMID: 28982112; PMCID: PMC5729468; DOI: 10.1038/bjc.2017.349;

B Peters ML, Miksad RA. Cabozantinib in the treatment of hepatocellular carcinoma. Future Oncol. 2017 Sep; 13(22):1915-1929. PMID: 28703624

Kasumova GG, Eskander MF, de Geus SWL, Neto MM, Tabatabaie O, Ng SC, Miksad RA, Mahadevan A, Rodrigue JR, Tseng JF. Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy. Surgery. 2017 Aug; 162(2):275-284.View Related Profiles.

Tseng, Jennifer
Miksad, Rebecca

PMID: 28487044; DOI: 10.1016/j.surg.2017.03.009;

Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 04 20; 35(12):1341-1367. PMID: 28148207

Martin RC, Bruenderman E, Cohn A, Piperdi B, Miksad R, Geschwind JF, Goldenberg A, Sanyal A, Zigmont E, Babajanyan S, Foreman P, Mantry P, McGuire B, Gholam P. Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry. Am J Surg. 2017 Apr; 213(4):688-695. PMID: 28318501

Kasumova GG, Miksad RA, Tseng JF. Cutting Through Confusion: Multimodality Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. J Oncol Pract. 2016 10; 12(10):924-925.View Related Profiles.

Tseng, Jennifer
Miksad, Rebecca

PMID: 27858559; PMCID: PMC5063190; DOI: 10.1200/JOP.2016.016923;

Miao R, Wu Y, Zhang H, Zhou H, Sun X, Csizmadia E, He L, Zhao Y, Jiang C, Miksad RA, Ghaziani T, Robson SC, Zhao H. Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer. Sci Rep. 2016 09 13; 6:33121. PMID: 27618777; PMCID: PMC5020615; DOI: 10.1038/srep33121;

de Geus SW, Evans DB, Bliss LA, Eskander MF, Smith JK, Wolff RA, Miksad RA, Weinstein MC, Tseng JF. Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis. Eur J Surg Oncol. 2016 Oct; 42(10):1552-60.View Related Profiles.

Tseng, Jennifer
Miksad, Rebecca

PMID: 27570116; DOI: 10.1016/j.ejso.2016.07.016;

Bhasin MK, Ndebele K, Bucur O, Yee EU, Otu HH, Plati J, Bullock A, Gu X, Castan E, Zhang P, Najarian R, Muraru MS, Miksad R, Khosravi-Far R, Libermann TA. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier. Oncotarget. 2016 Apr 26; 7(17):23263-81. PMID: 26993610; PMCID: PMC5029625; DOI: 10.18632/oncotarget.8139;

Pectasides E, Miksad R, Pyatibrat S, Srivastava A, Bullock A. Spontaneous Regression of Hepatocellular Carcinoma with Multiple Lung Metastases: A Case Report and Review of the Literature. Dig Dis Sci. 2016 09; 61(9):2749-54. PMID: 27038447

Peters ML, Tseng JF, Miksad RA. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. Clin Ther. 2016 Jul; 38(7):1622-35.View Related Profiles.

Tseng, Jennifer
Miksad, Rebecca

PMID: 27041411; DOI: 10.1016/j.clinthera.2016.03.006;

Griffith OL, Griffith M, Krysiak K, Magrini V, Ramu A, Skidmore ZL, Kunisaki J, Austin R, McGrath S, Zhang J, Demeter R, Graves T, Eldred JM, Walker J, Larson DE, Maher CA, Lin Y, Chapman W, Mahadevan A, Miksad R, Nasser I, Hanto DW, Mardis ER. A genomic case study of mixed fibrolamellar hepatocellular carcinoma. Ann Oncol. 2016 06; 27(6):1148-54. PMID: 27029710; PMCID: PMC4880064; DOI: 10.1093/annonc/mdw135;

Dagoglu N, Callery M, Moser J, Tseng J, Kent T, Bullock A, Miksad R, Mancias JD, Mahadevan A. Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer. J Cancer. 2016; 7(3):283-8.View Related Profiles.

Tseng, Jennifer
Miksad, Rebecca

PMID: 26918041; PMCID: PMC4747882; DOI: 10.7150/jca.13295;

Jahn B, Rochau U, Kurzthaler C, Hubalek M, Miksad R, Sroczynski G, Paulden M, Kluibenschädl M, Krahn M, Siebert U. Cost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria. Springerplus. 2015; 4:752. PMID: 26693110; PMCID: PMC4666888; DOI: 10.1186/s40064-015-1440-6;

Mahadevan A, Dagoglu N, Mancias J, Raven K, Khwaja K, Tseng JF, Ng K, Enzinger P, Miksad R, Bullock A, Evenson A. Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma. J Cancer. 2015; 6(11):1099-104.View Related Profiles.

Tseng, Jennifer
Miksad, Rebecca

PMID: 26516357; PMCID: PMC4615345; DOI: 10.7150/jca.13032;

Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015 Feb 20; 33(6):550-8. PMID: 25512453; PMCID: PMC4322258; DOI: 10.1200/JCO.2014.57.9151;

Gashin L, Tapper E, Babalola A, Lai KC, Miksad R, Malik R, Cohen E. Determinants and outcomes of adherence to recommendations from a multidisciplinary tumour conference for hepatocellular carcinoma. HPB (Oxford). 2014 Nov; 16(11):1009-15. PMID: 24888730; PMCID: PMC4487752; DOI: 10.1111/hpb.12280;

Miao R, Luo H, Zhou H, Li G, Bu D, Yang X, Zhao X, Zhang H, Liu S, Zhong Y, Zou Z, Zhao Y, Yu K, He L, Sang X, Zhong S, Huang J, Wu Y, Miksad RA, Robson SC, Jiang C, Zhao Y, Zhao H. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. J Hepatol. 2014 Oct; 61(4):840-9. PMID: 24859455

Beard RE, Hanto DW, Gautam S, Miksad RA. A comparison of surgical outcomes for noncirrhotic and cirrhotic hepatocellular carcinoma patients in a Western institution. Surgery. 2013 Sep; 154(3):545-55. PMID: 23777589

Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol. 2012 Aug 20; 30(24):2963-8.View Related Profiles.

Kulke, Matthew
Miksad, Rebecca

PMID: 22778320; PMCID: PMC4874232; DOI: 10.1200/JCO.2011.40.3147;

Miksad RA. When a decision must be made: role of computer modeling in clinical cancer research. J Clin Oncol. 2011 Dec 10; 29(35):4602-4. PMID: 22067392

Duvoux C, Kiuchi T, Pestalozzi B, Busuttil R, Miksad R. What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma? Liver Transpl. 2011 Oct; 17 Suppl 2:S147-58. PMID: 21714065; PMCID: PMC3417809; DOI: 10.1002/lt.22367;

Doherty GA, Miksad RA, Cheifetz AS, Moss AC. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. Inflamm Bowel Dis. 2012 Sep; 18(9):1608-16.View Related Profiles.

Moss, Alan
Miksad, Rebecca

PMID: 21905173; PMCID: PMC3381977; DOI: 10.1002/ibd.21904;

Mahadevan A, Miksad R, Goldstein M, Sullivan R, Bullock A, Buchbinder E, Pleskow D, Sawhney M, Kent T, Vollmer C, Callery M. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys. 2011 Nov 15; 81(4):e615-22. PMID: 21658854

Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011 Nov 15; 117(22):5094-102. PMID: 21538343; PMCID: PMC3417818; DOI: 10.1002/cncr.26165;

Miksad RA, Lai KC, Dodson TB, Woo SB, Treister NS, Akinyemi O, Bihrle M, Maytal G, August M, Gazelle GS, Swan JS. Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist. 2011; 16(1):121-32. PMID: 21212433; PMCID: PMC3228058; DOI: 10.1634/theoncologist.2010-0183;

Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist. 2010; 15(11):1179-91. PMID: 21045188; PMCID: PMC3227908; DOI: 10.1634/theoncologist.2009-0155;

Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad R, Fuchs CS, Ryan DP, Jain RK. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: kinetics and potential biomarker value. Clin Cancer Res. 2011 Feb 15; 17(4):918-27. PMID: 20843836; PMCID: PMC3023846; DOI: 10.1158/1078-0432.CCR-10-0515;

Kamo N, Dandapani SV, Miksad RA, Houlihan MJ, Kaplan I, Regan M, Greenfield TK, Sanda MG. Evaluation of the SCA instrument for measuring patient satisfaction with cancer care administered via paper or via the Internet. Ann Oncol. 2011 Mar; 22(3):723-9. PMID: 20716625; PMCID: PMC3042922; DOI: 10.1093/annonc/mdq417;

Mahadevan A, Jain S, Goldstein M, Miksad R, Pleskow D, Sawhney M, Brennan D, Callery M, Vollmer C. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2010 Nov 01; 78(3):735-42. PMID: 20171803

Swan JS, Miksad RA. Measuring the quality-of-life effects of diagnostic and screening tests. J Am Coll Radiol. 2009 Aug; 6(8):567-75. PMID: 19643385

Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009 Jun 20; 27(18):3027-35. PMID: 19470923; PMCID: PMC2702235; DOI: 10.1200/JCO.2008.20.9908;

Miksad RA, Gönen M, Lynch TJ, Roberts TG. Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer. J Clin Oncol. 2009 May 01; 27(13):2245-52. PMID: 19307513; PMCID: PMC2674005; DOI: 10.1200/JCO.2008.16.2586;

Miksad RA, Lai KC, Stein MC, Healy ME, Rojas R, Krajewski KM, Zhu AX. Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer. J Gastrointest Cancer. 2009; 40(3-4):119-22. PMID: 19894033; PMCID: PMC3417813; DOI: 10.1007/s12029-009-9086-7;

Wright DR, Wittenberg E, Swan JS, Miksad RA, Prosser LA. Methods for measuring temporary health States for cost-utility analyses. Pharmacoeconomics. 2009; 27(9):713-23. PMID: 19757865

Molokwu CN, Appelbaum JS, Miksad RA. Detection of prostate cancer following gender reassignment. BJU Int. 2008 Jan; 101(2):259; author reply 259-60. PMID: 18173830

Miksad RA, Zietemann V, Gothe R, Schwarzer R, Conrads-Frank A, Schnell-Inderst P, Stollenwerk B, Siebert U. Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care. 2008; 24(4):371-83. PMID: 18828930; PMCID: PMC4744081; DOI: 10.1017/S0266462308080495;

Mühlberger N, Sroczynski G, Esteban E, Mittendorf T, Miksad RA, Siebert U. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: a systematic review commissioned by the German Federal Ministry of Health. Int J Technol Assess Health Care. 2008; 24(2):184-92. PMID: 18400122

Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol. 2007 Oct 01; 25(28):4506-7; author reply 4508. PMID: 17906218

Silva G, Miksad R, Freedman SD, Pascual-Leone A, Jain S, Gomes DL, Amancio EJ, Boggio PS, Correa CF, Fregni F. Treatment of cancer pain with noninvasive brain stimulation. J Pain Symptom Manage. 2007 Oct; 34(4):342-5. PMID: 17903664; PMCID: PMC2763264; DOI: 10.1016/j.jpainsymman.2007.06.002;

Miksad RA, Bubley G, Church P, Sanda M, Rofsky N, Kaplan I, Cooper A. Prostate cancer in a transgender woman 41 years after initiation of feminization. JAMA. 2006 Nov 15; 296(19):2316-7. PMID: 17105793

Costa DB, Miksad RA, Buff MS, Wang Y, Dezube BJ. Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient. J Natl Med Assoc. 2006 Jul; 98(7):1183-7. PMID: 16895293; PMCID: PMC2569475

Levy NC, Miksad RA, Fein OT. From treatment to prevention: the interplay between HIV/AIDS treatment availability and HIV/AIDS prevention programming in Khayelitsha, South Africa. J Urban Health. 2005 Sep; 82(3):498-509. PMID: 16049203; PMCID: PMC3456048; DOI: 10.1093/jurban/jti090;

Miksad R, de Lédinghen V, McDougall C, Fiel I, Rosenberg H. Hepatic hydrothorax associated with vitamin a toxicity. J Clin Gastroenterol. 2002 Mar; 34(3):275-9. PMID: 11873112

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 97 publications over 22 distinct years, with a maximum of 11 publications in 2019

Bar chart showing 97 publications over 22 distinct years, with a maximum of 11 publications in 2019

Year	Publications
2002	1
2005	1
2006	2
2007	2
2008	3
2009	5
2010	4
2011	6
2012	1
2013	1
2014	3
2015	2
2016	9
2017	7
2018	7
2019	11
2020	6
2021	9
2022	6
2023	5
2024	5
2025	1

Media Mentions
Tweets

Note: X.com has changed/limited the ability to embed tweets directly in external sites and we are investigating ways to restore that functionality in BU Profiles. In the meantime we are displaying a link to your x.com profile in the Websites section above.

Robert Winn, Rebecca Miksad, Dana Rollison: We must use real-world data and lessons from COVID to improve care, equity in communities we serve

The Cancer Letter 5/13/2022

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

hepatocellular carcinoma (HCC)
pancreatic cancer
bile duct cancers liver
directed therapy
Hepatocellular Cancer
neuroendocrine tumors
colon cancer
gastric cancer
Cholangiocarcinoma
Medical Oncology

Contact for Mentoring:

820 Harrison Avenue
Boston MA 02118
Google Map

617.638.7011

Download vCard

Miksad's Networks

Click the "See All" links for more information and interactive visualizations

Concepts

See all (365) concept(s)

Media Mentions

The Cancer Letter

Co-Authors

See all (3) people

Similar People

See all (60) people

Same Department

Search Department